In the UK, the National Institute for Clinical Excellence has recommended the use of neuraminidase inhibitors for elderly and at-risk patients who present with influenza-like illness within 36 hours of symptom onset. However, few data exist to enable primary care trusts to evaluate the logistics and costs of prescribing. We sought to determine, during a confirmed influenza outbreak, the proportion of eligible patients who currently present in time to benefit from treatment with a neuraminidase inhibitor, and to develop the findings into a model for evaluating potential prescribing costs. Within a single primary care group, demographic and co-morbidity data were collected on all patients consulting their general practitioner or attending an out-of-hours centre with influenza-like illness during the outbreak period.
INTRODUCTION
In November 2000, the National Institute for Clinical Excellence (NICE) issued guidance to the UK National Health Service (NHS) on the use of zanamivir (Relenza, GlaxoSmithKline) for the treatment of influenza 1 . Zanamivir was recommended for use in patients with chronic respiratory disease, significant cardiovascular disease, diabetes mellitus, the immunocompromised, and persons aged 65 years and over irrespective of co-morbidity. To be eligible, patients should have presented with an influenza-like illness within 36 hours of illness onset and be able to begin treatment within 48 hours of illness onset.
Health authorities and primary care organizations were asked to incorporate this advice into their capacity (winter) plans. However, no clear estimates existed regarding the proportion of patients who would present in time to benefit from treatment. The NHS Health Technology Assessment Programme Report 2 , which supported the current guidance, referred to only one study, which suggested that 12.5% of patients with influenza-like illness presented within 48 hours 3 . However, it was unclear whether these data had been collected during a known outbreak period. It was also unclear whether any distinction had been made between at-risk and 'healthy' patients, who might have differed in terms of the time between onset of symptoms and receipt of medical attention. Furthermore, the 48-hour period between illness onset and presentation used in the study did not correspond to the time limit of 36 hours stipulated by NICE. In contrast, during a known outbreak in 1999/2000, Ross et al. noted that 23% of all patients and 21% of at-risk patients consulted within 48 hours 4 . Patients aged 45 years and over were less likely to consult within 48 hours than younger patients, especially children. However, these data were not available in time to be taken into account by NICE 1 .
The original NICE guidance was reviewed in summer 2002, when zanamivir was considered in parallel with oseltamivir (Tamiflu, Hoffmann La Roche) and amantadine (Lysovir, Alliance).
In the latest guidance, both zanamivir and oseltamivir have been approved for the treatment of elderly and at-risk adults who present within 36 hours of illness onset and can begin treatment within 48 hours 5 . In addition, oseltamivir has been approved for the treatment of at-risk children and for prophylaxis in at-risk individuals unprotected by vaccine and living in residential care 5 . To anticipate demand for treatment, information is needed on the number of patients in appropriate at-risk groups who are likely to present within 36 hours of illness onset.
To add robustness to the previous estimates made by Ross and colleagues, we conducted a prospective study of the timing of consultations for influenza-like illness in relation to symptom onset in the same season (1999/2000); however, we took into account the exact 36-hour interval from illness onset to presentation specified in the original NICE guidance 1 , and the at-risk patient definitions specified in the latest guidance 5 . We used these data to produce a model for forecasting the likely impact of treating influenzalike illness according to NICE guidance, taking into account the variable intensity of seasonal influenza outbreaks. We also considered the potential impact of different models of primary care. In this paper we show how such locally generated data can be used to evaluate local access to care and potential prescribing costs.
METHODS
We asked all general practices in one primary care group, in a market town in Trent Region (16 practices, registered population 110 491) to collect information on all patients attending with influenza-like illness between 16 December 1999 and 27 January 2000. This period coincided with increased influenza activity identified by the RCGP Weekly Returns Service 6 . Data were collected on basic demography, time and date of symptom onset, time and day of consultation, and whether each patient belonged to an atrisk group as defined in the latest NICE guidance 5 .
The data were analysed to explore which patients with influenza-like illness were more likely to attend within the 36 hours of illness onset. Cross tabulations and chi-squared analyses were performed after restriction of data to those patients in whom the exact timings of symptom onset and consultation were both known. Multivariate linear regression was then used to control for confounding (SPSS version 10.1). The data were also analysed to estimate average weekly consultation rates over the outbreak period, the proportion of patients defined as at-risk, and the proportion of these who presented within 36 hours of illness onset. By combining these figures with data from the Weekly Returns Service, we produced a model that estimated the number of patients eligible for treatment in any given week of an outbreak, depending upon the consultation rate for influenza-like illness. The potential impact on prescribing budgets was also modelled for two influenza seasons associated with small outbreaks (1988/89 and 1991/92) and the large epidemic in 1989/90. For weeks in which consultations for influenzalike illness reached 50 per 100 000 or above (the threshold defined by NICE for use of a neuraminidase inhibitor) 1 the number of patients who would be expected to attend their general practitioner with influenza-like illness and be eligible for treatment was calculated as follows:
Weekly consultation rate for influenza-like illness6proportion of general practitioner influenza-like illness attenders who were high risk6proportion of these patients attending within 36 hours of illness onset.
Similarly, the number of eligible patients who would be expected to attend the out-of-hours centre was estimated as follows:
Weekly consultation rate for influenza-like illness6the additional proportion of patients attending the out-of-hours centre over and above those attending their general practitioner6proportion of out-of-hours centre influenza-like illness attenders who were high-risk6proportion of these patients attending within 36 hours of illness onset.
Weekly figures were then aggregated to estimate the total number of eligible patients in each influenza season. Prescribing costs were calculated on the assumption of basic NHS costs of £24 per treatment course for zanamivir and £18.18 for oseltamivir 7 .
RESULTS
Practices involving twenty-eight individual general practitioners (total patient list size 60 520; 57% of the primary care group population) agreed to collect data. Doctors working at an out-of-hours centre serving the same population also agreed to collect data.
Over the outbreak period, 423 consultations for influenza-like illness were reported by the participating general practitioners, giving an average weekly consultation rate of 117/100 000 population. If the consultation rate among the patients of general practitioners who did not participate was the same, about 773 patients in the entire primary group would have attended their general practitioner with influenza-like illness during the outbreak. A further 397 patients with influenza-like illness attended the out-of-hours centre over the same period. Table 1 shows the results of the univariate analysis of factors associated with attending within 36 hours of illness onset. Data on the exact timing of symptom onset and consultation were recorded for 705 of the 820 patients in the study (86%). Patients aged less than 12 years, those defined by NICE to be at-risk and those who attended the out-of-hours centre were all significantly more likely to present within 36 hours than others. Those aged less than 12 years were also significantly more likely to attend the out-of-hours centre than older patients (P50.0005). The multivariate analysis confirmed that age less than 12 years (P=0.004), an underlying illness that put the patient at risk of influenza complications (P=0.005), and attendance at the out-of-hours centre (P50.0005) were all independent predictors of consulting within the 36-hour time window.
Of the 423 patients who attended their general practitioner with influenza-like illness, 117 (28%) met the NICE criteria for being at-risk. Of these 117 patients, 24 (20%: 95% confidence interval, 13-28%) saw their general practitioner within 36 hours of illness onset. Similarly, of the 397 patients who attended the out-of-hours centre, 149 (38%) were at-risk, according to NICE guidance, and 70 (47%: 95% confidence interval 39-55%) were seen within 36 hours of illness onset.
Thus, the weekly number of patients expected to attend their general practitioner for influenza-like illness and be eligible for treatment was: [weekly consultation rate for influenza-like illness60.2860.20]. The weekly number of eligible patients expected to attend the out-of-hours centre was calculated as: [weekly consultation rate for influenzalike illness60.5160.3860.47].
Modelling of our results against observed national consultation rates for influenza-like illness illustrates the inter-season variability in prescribing costs that might be encountered. In 1988/1989, a season of low influenza activity, 149 patients per 100 000 population would have been eligible for treatment with neuraminidase inhibitors at a cost of £3576 for zanamivir and £2709 for oseltamivir (calculations based on NHS prices). In 1991-1992, another season of low activity, this treatment burden would have been 138 patients per 100 000 at a cost of £3312 and £2509, respectively. However, in 1989/1990, when a severe epidemic occurred, 248 patients would have been eligible, at a cost of £6816 and £5163, respectively.
DISCUSSION
There has been considerable debate in both lay and medical press about the budgetary implications of zanamivir and other neuraminidase inhibitors. In this paper we illustrate how such estimates can be made at local level from simple local observations. Nevertheless, interpretations of the results must take account of several unresolved issues.
First, the study took place in the season before NICE guidance was issued and it is not yet possible to judge whether consultation rates for influenza-like illness will increase if neuraminidase inhibitors become widely available through NHS primary care. NICE guidance was issued in time for the 2000/01 winter season but the drugs were prescribed infrequently during this season and there was no evidence of increases in consultation rates by patients seeking such prescriptions. This may have been because of low levels of influenza activity in 2000/01; however, this explanation seems unlikely as other respiratory viral illnesses whose level of circulation each winter is less variable than influenza are commonly mislabelled by patients as 'flu' and these patients would still have requested treatment. If in the future the benefits of treating influenza with neuraminidase inhibitors are more widely appreciated by patients, it is possible that some will alter their consulting behaviour (and possibly the reporting of their symptoms in order to qualify for treatment). Similarly if general practitioners perceive large benefits for their patients arising from such treatment, it is possible that the definition of at-risk status and the 36-hour period from illness onset to presentation will be interpreted loosely or sympathetically to include more patients than strictly meet the eligibility criteria laid down by NICE. Both of these factors would lead to prescribing costs that are higher than those that we have estimated.
It is equally possible that, within this study, the proportion of eligible patients actually seen within 36 hours of illness onset (20% through conventional general practitioner consultations and 47% though the out-of-hours centre) reflected the maximum capacity of NHS primary care in that location to provide consultations within the requisite time period-i.e. the appointments system may be at saturation point. This is perhaps more likely for conventional general practitioner consultations than for the out-of-hours centre. Indeed, it seems intuitively correct that the disparity between the proportions of eligible patients seen within 36 hours of illness onset through conventional consultations and through the out-of-hours centre reflects differences in service configuration and accessibility. We found that children aged less than 12 years with influenza-like illness were significantly more likely to attend the out-of-hours centre than older patients and were also more likely to attend within 36 hours of illness onset. However, even after this confounding effect was controlled for, patients attending the out-of-hours centre were significantly more likely than those attending conventional general practitioner surgeries to consult within 36 hours of illness onset. After adjustment for both age and location of consultation, at-risk patients were also significantly more likely to present within 36 hours of illness onset. Increased availability of out-of-hours centres, including NHS Direct walk-in centres, could lead to higher numbers of eligible patients being able to receive neuraminidase inhibitors within 36 hours of symptom onset. This would increase prescribing costs.
Our study took place in a market town in Trent. Access to primary care may be different in this setting from that in other settings such as inner cities. We did not consider prophylactic use, which is more difficult to estimate because it depends on the timely detection of influenza in an institutional setting. According to our model, a typical primary care trust serving a population of 100 000 could expect some 140 patients to receive neuraminidase inhibitors during a winter season with low-level influenza activity. This would rise to about 300 during a winter of exceptionally high activity such as 1989/90. A general practitioner with a list size of 2000 patients might therefore see around 3 eligible patients in a non-epidemic year and 6 in a severe epidemic. The potential impact on individual general practitioner prescribing budgets would therefore be modest, ranging from £72 to £144 per season with zanamivir and £55 to £109 with oseltamivir. It is noteworthy that, using separate data, NICE likewise estimated a baseline of 3 eligible patients per general practitioner per season; however, the maximum estimate suggested by NICE was 17 per general practitioner per season, after allowance for potential changes in consultation and for off-guidance prescribing 1 .
In this paper we have demonstrated an approach to winter planning driven by locally collected data. We have highlighted that only 20% of at-risk patients consulting through conventional general practice and 47% of those consulting through out-of-hours centres currently do so in time to be eligible for treatment. Our estimate is remarkably consistent with previous estimates that 21% of at-risk patients present within 48 hours of symptom onset 4 . However, the proportion of similar patients presenting within 48 hours at out-of-hours centres was strikingly different. It is disappointing that only a small proportion of patients recommended for treatment by NICE are likely to consult their general practitioner within an appropriate time frame for initiation of treatment. In this respect, our study provides additional information about the potential impact of different models of care such as an out-of-hours centre. It also highlights the vital importance of annual immunization of elderly and high-risk patients.
In the NHS HTA Programme Report, which supported the NICE guidance on zanamivir, it was noted that if rates of hospital admission prove to be reduced by neuraminidase inhibitors, use of these agents would probably be more effective and cheaper than standard symptomatic treatment 2 . Some evidence of lower hospital admission rates is now emerging 8 . If use of neuraminidase inhibitors in at-risk groups can indeed be shown to be cost-effective or even cost-saving, special measures will be needed to gain the full benefits.
This study indicates that important questions about the delivery of primary care services must be resolved before a large proportion of elderly and at-risk patients will be able to secure timely access to treatment with neuraminidase inhibitors. The difficulties with prescription of these drugs contrast with the ease of annual influenza immunization 9 , which retains its overriding importance in limiting the impact of influenza.
